Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

(HZNP)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
62.97 USD   +0.54%
09/22Horizon Therapeutics plc Expands Commitment to Education Equity, STEAM Careers and Historically Black Colleges and Universities, Adding Meharry Medical College as Horizon Scholars Partner
BU
09/21Horizon Therapeutics plc Announces EB Research Partnership Receives 2022 Horizon Prize, Powered by MIT Solve
BU
09/19Horizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Horizon Therapeutics Files for Brazilian Approval of Autoimmune Disease Treatment

06/15/2022 | 09:38am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AQUAPORIN A/S 3.07% 67.2 Delayed Quote.-39.46%
EURO / BRAZILIAN REAL (EUR/BRL) 1.17% 5.0976 Delayed Quote.-20.56%
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY 0.54% 62.97 Delayed Quote.-41.56%
All news about HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
09/22Horizon Therapeutics plc Expands Commitment to Education Equity, STEAM Careers and Hist..
BU
09/21Horizon Therapeutics plc Announces EB Research Partnership Receives 2022 Horizon Prize,..
BU
09/19Horizon to Highlight Novel Insights in Gout Care During the American College of Rheumat..
BU
09/16Horizon Therapeutics plc Makes Founding Gift to Support the University of Notre Dame's ..
BU
09/15Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA (pegloticase) Injection w..
AQ
09/14Horizon Therapeutics plc Joins the International Agency for the Prevention of Blindness..
AQ
09/14Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection ..
BU
09/14Horizon Therapeutics plc Announces Data from the MIRROR Randomized Controlled Trial of ..
CI
09/13TRANSCRIPT : Horizon Therapeutics Public Limited Company Presents at Morgan Stanley 20th A..
CI
09/13Horizon Therapeutics plc Joins the International Agency for the Prevention of Blindness..
BU
More news
Analyst Recommendations on HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
More recommendations
Financials (USD)
Sales 2022 3 562 M - -
Net income 2022 478 M - -
Net cash 2022 164 M - -
P/E ratio 2022 24,8x
Yield 2022 -
Capitalization 14 507 M 14 507 M -
EV / Sales 2022 4,03x
EV / Sales 2023 3,30x
Nbr of Employees 2 015
Free-Float 98,8%
Chart HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Duration : Period :
Horizon Therapeutics Public Limited Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 62,97 $
Average target price 105,64 $
Spread / Average Target 67,8%
EPS Revisions
Managers and Directors
Timothy P. Walbert Chairman, President & Chief Executive Officer
Aaron L. Cox Chief Financial Officer & Executive Vice President
Jeffrey W. Sherman CMO, Executive VP-Development & Regulatory Affairs
Michael A. DesJardin Executive VP-Technical Operations & Quality
Jeffrey D. Kent Executive VP-Medical Affairs & Outcomes Research
Sector and Competitors
1st jan.Capi. (M$)
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY-41.56%14 507
JOHNSON & JOHNSON-2.54%438 337
ELI LILLY AND COMPANY12.54%295 941
ROCHE HOLDING AG-18.41%259 291
ABBVIE INC.5.66%252 944
PFIZER, INC.-25.35%247 392